Testosterone Deficiency

Abdulmaged M. Traish, MBA, PhD, a, b Martin M. Miner, MD, b, c Abraham Morgentaler, MD, b, d Michael Zitzmann, MD b, e

a Department of Biochemistry and Division of Urology, Boston University School of Medicine, Boston, Mass; b The International Society on Men’s Health Testosterone Consensus Group; c Department of Family Medicine and Urology, Warren Albert School of Medicine, Brown University, Providence, RI; d Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; e Centre for Reproductive Medicine and Andrology/Clinical Andrology Domagkstrasse 11 University Clinics Muenster, Germany

ABSTRACT

Testosterone deficiency (TD) afflicts approximately 30% of men aged 40-79 years, with an increase in prevalence strongly associated with aging and common medical conditions including obesity, diabetes, and hypertension. A strong relationship is noted between TD and metabolic syndrome, although the relationship is not certain to be causal. Repletion of testosterone (T) in T-deficient men with these comorbidities may indeed reverse or delay their progression. While T repletion has been largely thought of in a sexual realm, we discuss its potential role in general men’s health concerns: metabolic, body composition, and all-cause mortality through the use of a single clinical vignette. This review examines a host of studies, with practical recommendations for diagnosis of TD and T repletion in middle-aged and older men, including an analysis of treatment modalities and areas of concerns and uncertainty.

© 2011 Elsevier Inc. All rights reserved.

KEYWORDS: Cardiovascular disease; Erectile dysfunction; Insulin resistance; Metabolic syndrome; Testosterone

CASE STUDY EXAMPLE

A 52-year-old man of Caucasian descent presented with erectile dysfunction (ED), diminished libido, and fatigue. He took no medications and was otherwise healthy. He was 5 feet, 7 inches tall (170 cm) and weighed 217 pounds (98 kg), with a body mass index of 34 kg/m² and a waist circumference of 43 inches (109.2 cm). His blood pressure was 135/80 mm Hg. Laboratory values were all normal except for serum total testosterone of 270 ng/dL (9.37 nmol/L) (normal reference range 300-1000 ng/dL [10.4-34.7 nmol/L]) and fasting serum glucose of 110 mg/dL (6.1 mmol/L) (normal 67-99 mg/dL [3.7-5.5 mmol/L]), indicating a component of metabolic syndrome (MetS). What are the diagnostic, prognostic, and therapeutic issues in a man with symptomatic testosterone deficiency associated with the metabolic syndrome?

THE CLINICAL PROBLEM

Hypogonadism, henceforth referred to as testosterone deficiency (TD), afflicts approximately 30% of men aged 40-79 years, and its prevalence is associated with aging. The prevalence values differ among the different studies due to assessment based on population surveys or clinical settings. Clinical symptoms of TD include fatigue, decreased libido, ED, and negative mood states. TD also is associated with changes in body composition, including decreased lean body mass, increased fat mass, and decreased bone mineral density. A significant increased risk of TD is noted in association with common medical conditions such as obesity, type 2 diabetes mellitus (T2DM), and hypertension. In addition, a strong relationship was observed between TD and the MetS. Whereas treatment of TD has been initiated primarily for relief of sexual symptoms, there is now increasing interest among clinicians in addressing the potential adverse metabolic and general health issues associated with TD. Further, recent studies in
Women with complete androgen insensitivity syndrome showed increased body fat, abnormal values of cholesterol, and homeostasis model assessment of insulin resistance (HOMA-IR), suggesting that disruption of androgen signaling in women also is associated with metabolic disorders. However, there are limited sources to guide decision-making in commonly seen cases where T replacement therapy (TRT) may be considered, such as in the aforementioned case vignette. It should be noted that African-Americans and Hispanics appear to have a higher risk of developing insulin resistance and type 2 diabetes compared with non-Hispanic whites. Other studies, however, suggested that the number of insulin-sensitive subjects with type 2 diabetes is low and similar among non-Hispanic whites, Hispanics, and African-Americans in the US, and suggested that some ethnic variability exists.

**TD: SIGNS, SYMPTOMS, AND PREVALENCE**

Table 1 lists the signs and symptoms of TD; the most common symptoms are sexual dysfunction (low libido or ED) and chronic fatigue. The prevalence of TD increases with age, ranging from 9% in men in their 50s to 91% of those in their 80s. Mulligan et al. found that the rate of TD was ~38.7% in men aged ≥45 years (n = 2165) who visited a primary care provider’s office. Although TD is more common among men with certain comorbidities, the decrease in T levels observed with age appears unrelated to illness. Free T fell by about 1.4% per year in men aged 39 to 70 years (n = 1709). Data from the Massachusetts Male Aging Study of approximately 1700 community-dwelling men showed that T levels among men with ≥1 comorbid condition (eg, obesity, cancer, coronary heart disease, hypertension, diabetes, prostate problems) remained 10%-15% lower than those of the control group of subjects, but the rate of decline in free T was similar. In the clinical case presented here, the patient exhibited TD and features of the MetS. The clinical question is whether there is a role for TRT as treatment for the patient’s sexual symptoms and MetS.

### CLINICAL SIGNIFICANCE

- Testosterone deficiency is a highly prevalent and under-diagnosed condition associated both with aging and with common medical comorbidities.
- A bidirectional inverse relationship exists between the presence of the number of components of the metabolic syndrome and testosterone levels.
- Testosterone deficiency has a strong association with all-cause mortality and cardiovascular disease risk.
- Early evidence suggests that testosterone replacement therapy may reverse early diabetes mellitus, or improve diabetic control.
- Testosterone replacement therapy is often prescribed to ameliorate sexual signs and symptoms, but may affect improved domains of overall male health.

**TD and All-Cause Mortality and Cardiovascular Disease (CVD) Risk**

Epidemiologic studies have identified significant associations between T levels and all-cause and cardiovascular death in general populations of men aged ≥40 years old (Figure 2). Mortality rate over a mean of 4.3 years for 858 veterans with normal, equivocal (one normal, one low measurement), and low T levels was 20.1%, 24.6%, and 34.9%, respectively. A larger (2314 men, aged 40-79 years), longer (average 7-year follow-up) nested case-control study found that every 173 ng/dL (6.0 nmol/L) increase
in serum T was associated with a 21% lower risk of all-cause death after excluding deaths within the first 2 years and controlling for multiple variables (age, body mass index, systolic blood pressure, cholesterol, cigarette smoking, diabetes, alcohol intake, physical activity, social class, education, and sex hormone-binding globulin).

The Rancho Bernardo study (n = 794 men, aged 50-91 years, average follow-up 11.8 years, but up to 20 years) also found that total and bioavailable T were inversely related to risk of death.

Caminiti et al. show, in a double-blind, placebo-controlled, randomized trial of 70 elderly patients with chronic heart failure, that long-acting intramuscular T supplementation on top of optimal therapy improves functional exercise capacity, muscle strength, insulin levels, and baroreflex sensitivity.

In men at increased risk for cardiovascular events, it may be advisable to obtain cardiology consultation before institution of testosterone therapy.

Data from recent randomized placebo-controlled trials of TRT in elderly frail men with limited mobility suggested potential improvements in physical function when T levels were maintained in the physiological range. However, negative cardiovascular risks in older, sicker group men with subclinical vascular disease were noted when T levels were maintained in the higher range. It should be noted that in the latter study, the small sample size, older and sicker population, and mobility limitations precludes the generalizability of these findings.

In contrast to the study by Srinivas-Shankar et al., which showed no serious cardiac adverse events, the Testosterone in Older Men study suffers from serious limitations, these include: patients with subclinical cardiovascular diseases and high prevalence of hypertension, diabetes, hyperlipidemia, and obesity; selection of subjects based on T levels only instead of in combination with clinical symptoms; inadequate randomization; and a dose-seeking study with T doses administered which exceeded those cited in the Endocrine Society Recommendations.

It should be pointed out that monitoring of the adverse events was not the primary end point, and reporting of these events was carried out by telephone interviews of subjects.
or reviewing external medical records. Thus, subjective feelings of tachycardia, syncope of unknown origin, arterial hypertension, and myocardial infarctions were all used as cardiovascular adverse events. In fact, in a recent meta-analysis, it was concluded that “the adverse effects of testosterone therapy include an increase in hemoglobin and hematocrit and a small decrease in high-density lipoprotein cholesterol but pointed to no association with cardiovascular events.”62 In addition, several unexplainable observations cast more doubt on the conclusions of this study, including the observation that diabetes and smoking reduced the risk of a cardiac event, and treatment with high T doubled the risk, and normal to high hematocrit increased risk 4- to 5-fold. Despite these unexplained anomalies, the authors drew broad conclusions on the adverse effect of TRT on cardiovascular health in these frail and immobile men. Indeed, the authors stated that “the lack of a consistent pattern in these events and the small number of overall events suggest the possibility that the differences detected between the 2 trial groups may have been due to chance alone.”57

Can TRT Reverse or Ameliorate MetS or Early Type 2 Diabetes?
MetS is associated with the risk of developing insulin resistance, T2DM, and CVD, and a higher risk of incident CVD and mortality.63 MetS is associated with a 2-fold increase of 5- to 10-year risk of CVD.64 Furthermore, the syndrome confers a 5-fold increase in risk for T2DM.64 Despite this evidence, the clinical use of this category, and in particular its utility as a predictor of CVD, has been the subject of vigorous criticism.14,15,37,64,65 Accordingly, recent data from a survey involving 880 community-dwelling men supported the construct that MetS is not better than the sum of its components in addressing cardiovascular risk.66

The level of evidence supporting TRT in the treatment of MetS, T2DM, and CVD varies because TRT administered in various formulations has differing outcomes on different aspects of clinical end points investigated. Specifically, reduction of body fat, especially intra-abdominal fat, is a key component in treating most individuals with MetS or T2DM, as well as many patients with atherosclerotic cardiovascular disease and dyslipidemia. We consider the evidence supporting TRT in reducing fat mass to be quite rigorous.67,68 Several randomized clinical trials,16,69-72 which enrolled 306 patients with MetS, with a mean follow-up of 58 weeks, have been reported. Of those trials, 3 were placebo controlled, whereas 2 open-label trials compared TRT with no treatment. In these trials—enrolling only patients with MetS—TD was defined according to different criteria and TRT was administered in different formulations and doses (Table 2). TRT was associated with a significant reduction of fasting plasma glucose, homeostasis model assessment index (HOMA), triglycerides, and waist circumference. In addition, an increase of high-density lipoprotein cholesterol also was observed, whereas no significant difference was observed for total cholesterol, blood pressure, and body mass index. It should be noted that in the aforementioned studies, some but not all of the patients recruited were receiving statins to reduce cholesterol. The levels of T may be affected by the use of statins because it has been reported that statins and glucose lowering agents use may reduce total but not bioavailable T.73,74

Heufelder et al16 randomized 32 men with TD who were newly diagnosed with T2DM to diet and exercise alone or diet and exercise combined with T gel therapy (50 mg once daily). Subjects had never received insulin or other glucose-lowering therapy, either before or during the trial and had a mean hemoglobin A1C (HbA1C) of 7.5%. At 52 weeks, the group receiving diet and exercise plus T improved significantly on mean serum T concentration, glycemic control (HbA1c), insulin levels and sensitivity, and C-reactive protein levels (P < .001 for all between-group comparisons). At study end, serum prostate-specific antigen concentrations were equivalent between groups, an indication of treatment safety.16

Value of TRT in TD Patients with ED and Low Libido
Studies of TRT on sexual function and performance vary in quality, although findings are generally consistent. Most studies show that TRT increased sexual awareness and arousal, erectile function, and the frequency of spontaneous erections, but is less consistent in enhancing sexual behavior and performance.75-85 Overall, the evidence demonstrates that TRT benefits some aspects of sexual desire, erectile function, and performance. This assessment is consistent with a recently published review86 and meta-analyses of randomized, placebo-controlled trials of TRT in men with sexual dysfunction and varying endogenous T levels.87 It is worth noting that, because vasculopathy is the most common cause of ED, it also can serve as an early marker for CVD.88 It is reasonable to obtain T results in men with ED, especially if associated with diminished libido or fatigue, and in men with an inadequate response to phosphodiesterase type-5 inhibitors. T action in these vascular beds may be mediated by several pathways, including vasodilation of blood vessels via activation of K+ channels or inhibition of Ca++ channels.89,90

Treatment of TD
A number of TRT preparations are currently available in the US market (Table 2). Intramuscular injections of short-acting T derivatives achieve good serum concentrations within 2-3 days, with levels returning to baseline in most men by 2 weeks, resulting in an injection schedule of 1-2 weeks. Men or their partners may be taught to perform the injection at home. Topical gels or patches provide a more stable serum-T concentration over time than injections. Patches currently available in the US are associated with a high rate of skin reaction, and their use has been largely supplanted by T gels. The main disadvantages of T gels are...
cost and a black box warning concerning transfer potential to women and children. A long-acting injection formulation (T undecanoate) is dosed every 10-12 weeks, and is available internationally but has not yet been approved for use in the US. T pellets provide 3-6 months of normal serum T, and are placed subcutaneously in the gluteal region via an in-office surgical implantation procedure under local anesthesia; this formulation also has some disadvantages such as extrusion of pellets post surgical procedure.

**Table 2 Testosterone Replacement Therapy Preparations (adapted from Bhasin et al. 2006)**

<table>
<thead>
<tr>
<th>Generic Name (Sample Brands)</th>
<th>Route</th>
<th>Dosing Regimen</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>T cypionate (Depo-Testosterone)</td>
<td>IM</td>
<td>200 mg/2 weeks, 300 mg/3 weeks, 400 mg/4 weeks</td>
<td>Long-acting, relatively inexpensive if self administered; flexibility of dosing.</td>
<td>Requires IM injection, does not mimic physiologic levels, creates peaks and troughs</td>
</tr>
<tr>
<td>T enanthate (aka ethanate) (Sustanon)</td>
<td>IM</td>
<td>1000 mg, followed by 1000 mg at 6 wk, and 1000 mg every 12 wks</td>
<td>Infrequent administration</td>
<td>Not approved in the US, IM injection of large volume (4 mL)</td>
</tr>
<tr>
<td>Injectable long-acting T undecanoate in oil (Nebido)</td>
<td>IM</td>
<td>5-10 g, delivers 50-100 mg dose daily</td>
<td>Flexible dosing, ease of application, good skin tolerability</td>
<td>Risk of transfer to a female partner or child by skin-to-skin contact if gel not completely dry, moderately high DHT levels</td>
</tr>
<tr>
<td>Transdermal hydroalcoholic gel (Androgel, Testim)</td>
<td>Topical</td>
<td>5 mg/day, applied to skin at bedtime</td>
<td>Mimics physiologic levels and diurnal pattern, ease of application, lesser increase in hemoglobin than injectable esters</td>
<td>Mimics physiologic dosing, contact dermatitis</td>
</tr>
<tr>
<td>Transdermal T patch (Androderm, Testoderm TTS)</td>
<td>Topical</td>
<td>One patch delivers 6 mg over 24 hours, applied daily</td>
<td>Mimics physiologic levels</td>
<td>To promote adherence, scrotal skin needs to be shaved, high DHT levels</td>
</tr>
<tr>
<td>Scrotal T patch (Testoderm)</td>
<td>Topical</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Buccal T (Striant)</td>
<td>Gum region</td>
<td>30 mg BID</td>
<td>Mimics physiologic levels</td>
<td>Gum-related adverse events in 16% of treated men</td>
</tr>
<tr>
<td>T pellets (Testopel)</td>
<td>SC</td>
<td>6-12 75-mg pellets implanted SC</td>
<td>Infrequent dosing</td>
<td>Requires surgical incision for insertions, pellets may extrude spontaneously</td>
</tr>
<tr>
<td>Oral T undecanoate (Andriol, Androxon, Understor, Restandol, Restinsol)</td>
<td>Oral</td>
<td>40-80 mg 2-3 times/day with meals</td>
<td>Convenience of oral administration</td>
<td>Not approved in the US, variable clinical responses, variable serum T levels, high DHT:T ratio</td>
</tr>
</tbody>
</table>

**BID = twice a day; DHT = dihydrotestosterone; IM = intramuscular; SC = subcutaneous.**

**Diagnosis of TD and TRT to Maintain Threshold Levels**

In addition, the genetic background relating to the patient responsiveness to androgens, hence, androgen receptor polymorphisms, are likely to play an inter-individual role. Furthermore, considerable uncertainty exists about 1) the accuracy of T assays, 2) the application of total or free T to clinical assessment of TD, and 3) the subject of age-stratification. Such considerations have to be taken into account when managing patients with TD who definitely need diagnosis and treatment: physicians have to use their clinical judgment and experience in such cases. For a practicing internist, we suggest the following approach to men with symptoms of TD:

Current treatment modalities appear relatively safe, and those adverse events that have been definitively associated with treatment are reversible with cessation of treatment. These include acne, gynecomastia, erythrocytosis, and edema. A number of additional risks have appeared in the literature, but their relationship to TRT is less well established. These include sleep apnea, worsening of urinary voiding symptoms, and prostate cancer. Standard forms of TRT do not appear to adversely affect lipid profiles or renal function. TRT does not appear to cause liver toxicity, with the exception of oral alkylated T preparations (eg, methyltestosterone), which should not be used for TRT for this reason.

**AREAS OF CONCERN AND UNCERTAINTY**

**Lack of Consensus about Biochemical Identification of Men with TD**

A key area of controversy relates to the biochemical determination of TD. There is no defined serum threshold for T
Obesity, erectile dysfunction, and the metabolic syndrome are associated with testosterone deficiency, even in men without the characteristic symptoms of diminished libido and fatigue. Although definitive evidence is lacking about the impact of testosterone therapy on metabolic endpoints, we present here an innovative approach based on supportive data regarding surrogate endpoints or early-term results. We believe existing data indicate that a diagnostic work-up is warranted in all of these men. (a) Total testosterone (T) has been the traditional method to diagnose testosterone deficiency. A number of suggested thresholds have been published. However, T assays produce highly variable results, and treatment must be individualized based on a combination of clinical presentation and biochemical results. Genetic variation may lead to symptoms of T deficiency in men with normal total T results. (b) Free T can be of diagnostic help in cases where total T does not correspond with clinical presentation. Clinical use of free T is complicated by the availability of a number of assays, and a lack of consensus regarding threshold values. We suggest 8 ng/dL (270 pmol/L) for calculated free T. The analog free T assay shows good correlation with calculated free T, corresponds with biological outcomes, and in our experience has clinical utility, albeit controversial. Values <1.5 ng/dL (52 pmol/L) obtained by the analog free T assay have been suggested as indicating the lower limit of normal. (c) Men with a suspicious prostate examination, or elevated prostate-specific antigen (PSA) should be referred to a urologist for consideration of prostate biopsy before initiation of T therapy. The use of T therapy in men with a prior history of prostate cancer has historically been an absolute contraindication to T therapy. This is an area of active investigation, with recent evidence suggesting the risk is considerably lower than once believed. However, we recommend that the nonspecialist refrain from initiating treatment in such men until there is clearer information as to which men with prior history of prostate cancer may be safely offered T therapy. Contraindications include the presence of elevated hemoglobin or hematocrit at baseline and the desire to initiate a pregnancy within the next 12 months. (d) A symptomatic response to T therapy is generally seen within 3 months. Monitoring should occur at least 2-3 times during the first year, and 1-2 times per year thereafter. Monitoring should include serum T, PSA levels, and hematocrit/hemoglobin. There is no need to measure liver or renal function tests for any of the routine T-therapy formulations. (e) Severe reductions in total T, (ie, <250 ng/dL [8 nmol/L]) are usually accompanied by symptoms or objective measures of T deficiency. Additional diagnostic studies may be indicated depending on the clinical presentation, for example, to exclude the presence of a pituitary mass, or genetic tests. (f) In cases of pituitary disease, genetic causes, unstable glucose control, testicular abnormalities, or the wish for paternity, a specialist should cooperate with the treating physician. PDE-5 = phosphodiesterase type-5.
that clearly distinguishes men who are T deficient from those who are not. Yet all published guidelines recommend one arbitrary threshold or another, generally ranging from 200 to 350 ng/dL (6.94-12.15 nmol/L). Variation in sex hormone-binding globulin levels also confounds the interpretation of bioavailable T levels. There is general agreement that free or bioavailable T provides a better estimation of T status, but there is uncertainty about the reliability of those assays. In addition, genetic variation may influence response to circulating T. For these reasons, we believe symptoms of testosterone deficiency, while often not diagnostic or pathognomonic, can play an important role in combination with blood tests in the diagnosis of testosterone deficiency.

A study by Wu et al\textsuperscript{94} to identify TD (late-onset hypogonadism) in the general population on the basis of an association between symptoms and levels, examined 3369 men between the ages of 40 and 79 years. The authors found that TD could be identified by presence of 3 sexual symptoms (decreased frequency of morning erection, decreased frequency of sexual thoughts, and erectile dysfunction) combined with a total T of 317 ng/dL (11 nmol/L) and a free T of <220 pmol/L (6.35 pg/mL). Although other nonsexual symptoms may relate to low T levels (physical and psychological) and are present, they do not appear to be a part of the condition of TD (late-onset hypogonadism). This finding in the field of TD is striking. An inverse relationship between an increasing number of sexual symptoms and a decreasing T level was observed. Although the prevalence of hypogonadism is much higher, the prevalence of late-onset hypogonadism is much lower: 2.1%. This underscores the importance of “using not only biochemical measures but also symptom-based criteria to prevent over-diagnoses of late-onset hypogonadism,” as the authors suggest.\textsuperscript{94} There are some concerns that this study failed to address, such as increased TD in individuals with comorbidities and metabolic disorders. Thus, defining TD based on purely reduced sexual function alone may not reflect accurately the experience of the clinical realm of the patient.\textsuperscript{2-7,95}

Those of us who critically examine the field of TD may not find this study\textsuperscript{94} as compelling as the most recent literature that has suggested the potential of T to remedy co-morbidities such as MetS and early T2DM. We have sought to take T solely out of the sexual realm and into the metabolic realm and as an overall marker of good health. While this study clearly demonstrates the association of T to sexual symptoms, it does not negate the work of examination of T’s impact on metabolic parameters necessary for healthy aging.

**TRT and Prostate Cancer (PCa) Risk**

The risks associated with TRT are listed in Table 2. An international study identified the greatest concern of physicians with regard to T therapy as potentially stimulating PCa.\textsuperscript{96} This concern stems from the use of androgen deprivation for the treatment of advanced prostate cancer. However, current data fail to demonstrate a significant association between serum androgen concentrations and prostate cancer. A large international study comprising 3886 men with PCAs and 6438 age-matched controls found no associations between PCAs risk and serum concentrations of T, calculated free T, or dihydrotestosterone.\textsuperscript{97,98}

A meta-analysis of 19 studies revealed no greater risk of PCAs in men diagnosed with TD who received placebo versus men who received T therapy.\textsuperscript{99} Although no long-term, large-scale studies on the safety of T therapy have been performed, evidence accumulated over the last 15 years strongly indicates that beyond the near-castrate range there is little, if any impact of changes in serum T on PCa growth.\textsuperscript{100}

**GUIDELINES**

Several guidelines have been published on the investigation, treatment, and monitoring of TD in men.\textsuperscript{101-107} The recently published guidelines\textsuperscript{61} on management of androgen deficiency revised the recommendations regarding therapy for older men, noted the relationship of TD with concomitant use of long-acting opiates, and added a brief commentary on the use of TRT in men with TD and a history of PCa deemed cured. Perhaps with the advent of these recommendations and the critical examination of the literature published in this field since 2003 and acknowledgement of the gaps of knowledge that continue to exist, this paradigm should be re-examined. It is noteworthy that these guidelines acknowledge that the strength of evidence underlying their recommendations is generally of poor quality, and editorials on this subject also arrived at similar conclusions.\textsuperscript{108,109}

**CONCLUSIONS AND RECOMMENDATIONS**

The patient presented in the clinical vignette is at increased risk for metabolic disorders/T2DM and is likely to die earlier from cardiovascular events than healthier men of his age. The presence of low-serum T concentrations provides an opportunity to treat his symptoms of fatigue and sexual dysfunction, and also to reverse or improve his metabolic status. We therefore recommend a 2- to 3-month trial of TRT, with appropriate monitoring to ensure that adequate serum T levels are achieved. At the end of this period the patient will be assessed for resolution of his symptoms and for physical and biochemical changes, including sexual function, waist circumference, fasting glucose, and lipid profile. Some evidence exists that a 3-month trial showed improvement in several parameters, including energy, mood, and sexual function.\textsuperscript{110} Our recommendations here are in general agreement with most published guidelines, with 2 primary sources of disagreement: one is that we emphasize clinical presentation over biochemical thresholds in the diagnosis of TD, and the second is that we believe there is adequate evidence to support the use of TRT in selected cases for metabolic and general health indications (Figure 3).\textsuperscript{111,112} It should be noted that while some parameters will be improved during a 3-month trial,\textsuperscript{110} anthropomorphic changes are unlikely to change during this short
period. If ED persists, a phosphodiesterase type-5 inhibitor will be prescribed. Diet and exercise recommendations will be encouraged and reinforced.

References

39. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral...


49. Traish AM, Feeley RJ, Guay A. Mechanisms of obesity and related pathologies: androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. FEBs J. 2009;276:5755-5767.


